Alpha 1-antitrypsin deficiency primary prevention: Difference between revisions
Mazia Fatima (talk | contribs) No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Alpha 1-antitrypsin deficiency}} | {{Alpha 1-antitrypsin deficiency}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} | ||
==Overview== | ==Overview== | ||
Revision as of 18:03, 22 January 2018
|
Alpha 1-antitrypsin deficiency Microchapters |
|
Differentiating Alpha 1-antitrypsin deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Alpha 1-antitrypsin deficiency primary prevention On the Web |
|
American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency primary prevention |
|
Alpha 1-antitrypsin deficiency primary prevention in the news |
|
Directions to Hospitals Treating Alpha 1-antitrypsin deficiency |
|
Risk calculators and risk factors for Alpha 1-antitrypsin deficiency primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Effective measures for the primary prevention of alpha 1-antitrypsin deficiency includes vaccination against hepatitis A and B is recommended to decrease the risk of liver disease.
Primary Prevention
Effective measures for the primary prevention of alpha 1-antitrypsin deficiency include:[1]
- Vaccination against hepatitis A and B is recommended to decrease the risk of liver disease.
References
- ↑ Stoller JK, Sandhaus RA, Turino G, Dickson R, Rodgers K, Strange C (2005). "Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem". Chest. 128 (4): 1989–94. doi:10.1378/chest.128.4.1989. PMID 16236846.